SCHEDULE 13G: Deep Track Capital Discloses 8.64% Stake in Jade Biosciences, Inc.
Beneficial Ownership Report
Deep Track Capital, LP, along with its affiliates Deep Track Biotechnology Master Fund, Ltd. and David Kroin, has disclosed a beneficial ownership of 8.64% in Jade Biosciences, Inc. common stock.
Summary
- Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin collectively reported beneficial ownership of 2,784,648 shares of Jade Biosciences, Inc. common stock.
- This ownership represents 8.64% of the total outstanding common stock of Jade Biosciences, Inc.
- The reporting persons hold shared voting and shared dispositive power over all 2,784,648 shares.
- The percentage of ownership is calculated based on 32,235,926 common shares outstanding as of April 28, 2025, as reported by Jade Biosciences, Inc. in an 8-K filing on May 1, 2025.
- The acquisition of these securities was not for the purpose of changing or influencing the control of Jade Biosciences, Inc.
Sentiment
Score: 5
Explanation: The document is a factual regulatory filing disclosing beneficial ownership and does not contain subjective information to assess sentiment beyond neutrality.
Future Outlook
NA
Industry Context
This Schedule 13G filing indicates a significant passive investment by Deep Track Capital, a specialized biotechnology investor, in Jade Biosciences, Inc. Such filings are routine disclosures required when an entity or group acquires more than 5% beneficial ownership of a company's stock, signaling a notable position taken by an institutional investor in the biotechnology sector.
Stakeholder Impact
- Shareholders: Provides increased transparency regarding significant institutional ownership in the company.
- Company Management: Notifies management of a new substantial shareholder, which may influence future investor relations and strategic considerations.
Key Dates
| Date | Description |
|---|---|
| 04/28/2025 | Date of event which required the filing of this statement; also the date for the calculation of shares outstanding. |
| 05/01/2025 | Date Jade Biosciences, Inc. filed its 8-K with the SEC, reporting 32,235,926 common shares outstanding. |
| 06/20/2025 | Date the Schedule 13G was signed and filed by the reporting persons. |
Keywords
Jade Biosciences, Deep Track Capital, Deep Track Biotechnology Master Fund, David Kroin, Schedule 13G, beneficial ownership, equity stake, common stock, investment fund, biotechnology investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.